ARMP Armata Pharmaceuticals Inc. Stock Quote

publish chart | save to portfolio | create alert

ARMP [AMEX]

Armata Pharmaceuticals Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.54	Insider Own	63.12%	Shs Outstand	18.40M	Perf Week	1.28%
Market Cap	58.80M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	0.00%	Shs Float	6.90M	Perf Month	-1.25%
Income	-20.10M	PEG	-	EPS next Q	-0.27	Inst Own	4.70%	Short Float	0.58%	Perf Quarter	-2.16%
Sales	0.30M	P/S	196.01	EPS this Y	72.10%	Inst Trans	1.87%	Short Ratio	2.68	Perf Half Y	-15.47%
Book/sh	1.34	P/B	2.37	EPS next Y	32.00%	ROA	-48.90%	Target Price	-	Perf Year	-27.63%
Cash/sh	0.86	P/C	3.70	EPS next 5Y	-	ROE	-78.70%	52W Range	2.52 - 6.92	Perf YTD	-2.46%
Dividend	-	P/FCF	-	EPS past 5Y	-14.90%	ROI	-	52W High	-54.19%	Beta	1.80
Dividend %	-	Quick Ratio	2.40	Sales past 5Y	-	Gross Margin	-	52W Low	25.79%	ATR	0.18
Employees	33	Current Ratio	2.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.13	Volatility	1.94% 5.80%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	56.90%	Profit Margin	-	Rel Volume	0.85	Prev Close	3.17
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	14.78K	Price	3.17
Recom	1.70	SMA20	-4.32%	SMA50	-3.01%	SMA200	-8.27%	Volume	12,604	Change	0.00%

Jun-19-19

Initiated

Ladenburg Thalmann

Buy

Nov-16-20 11:10PM	Brokers Are Upgrading Their Views On Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) With These New Forecasts Simply Wall St. -13.97%
Nov-15-20 07:17AM	Earnings Beat: Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
Nov-12-20 04:05PM	Armata Pharmaceuticals Announces Third Quarter 2020 Results and Provides General Corporate Update PR Newswire +7.95%
Oct-29-20 07:30AM	Armata Pharmaceuticals Issues Letter to Shareholders PR Newswire +7.00%
Oct-26-20 07:30AM	Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development PR Newswire
Oct-15-20 07:30AM	Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections PR Newswire +8.86%
Sep-29-20 07:30AM	Armata Pharmaceuticals to Present at the Virtual 2020 World Antimicrobial Resistance Congress PR Newswire
Sep-11-20 07:30AM	Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences PR Newswire
Aug-13-20 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update PR Newswire
Jun-30-20 06:05AM	Here's Why We're Watching Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Situation Simply Wall St.
Jun-17-20 07:30AM	Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections PR Newswire +10.33%
May-14-20 04:05PM	Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update PR Newswire
Apr-28-20 08:00AM	Armata Pharmaceuticals to Participate in the Maxim Group M-Vest Infectious Disease Virtual Conference: The Renaissance of the Anti-Infective Sector PR Newswire
Mar-30-20 07:30AM	Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc. PR Newswire
Mar-19-20 04:05PM	Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update PR Newswire -6.46%
Mar-18-20 08:00AM	Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation PR Newswire +10.94%
Feb-13-20 08:00AM	Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc. PR Newswire
Jan-29-20 08:04AM	Company News For Jan 29, 2020 Zacks -26.80%
Jan-28-20 07:00AM	Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs PR Newswire +73.84%
Nov-12-19 04:05PM	Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update PR Newswire
Oct-31-19 10:52AM	We're Keeping An Eye On Armata Pharmaceuticals's (NYSEMKT:ARMP) Cash Burn Rate Simply Wall St.
07:05AM	Armata Pharmaceuticals Issues Letter to Shareholders PR Newswire
Oct-21-19 07:05AM	Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive PR Newswire
Oct-16-19 07:05AM	Armata Pharmaceuticals Strengthens Clinical Team with Appointment of Dr. Heather Dale Jones as Medical Director PR Newswire
Oct-10-19 04:05PM	Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D. PR Newswire
Sep-19-19 07:05AM	Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference PR Newswire
Sep-12-19 09:00AM	Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa PR Newswire
Aug-14-19 04:05PM	Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update PR Newswire
Aug-02-19 03:27PM	How Much Of Armata Pharmaceuticals, Inc. (NYSEMKT:ARMP) Do Institutions Own? Simply Wall St.
Aug-01-19 10:30AM	Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference PR Newswire
Jun-18-19 07:01AM	Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York PR Newswire
Jun-03-19 07:01AM	Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada PR Newswire -5.96%
May-28-19 07:01AM	Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient PR Newswire +31.67%

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience